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SUMMARY
The effect ofcyclosporine (CsA) on the CH 12 murine B cell lymphoma was investigated to
determine whether sensitivity to this agent is retained by malignant B cells. This tumour
produces an antibody to bromelain-treated red blood cells and may represent transforma-
tion of a B cell with certain activation properties associated with early resting B cells. In in
vitro cultures, the growth and proliferation of CH 12 were inhibited by CsA in
concentrations of 01-1-0 pg/ml; these levels were ineffective against non-lymphoid
tumours, although some non-specific cell toxicity was noted at higher levels. IgM
antibody production, as measured by enzyme-linked immunosorbent assay (ELISA), was
inhibited over the same range. CH 12 cells stimulated by lipopolysaccharide, however,
were less sensitive to CsA than untreated cells. These studies indicate that malignant B
cells may be sensitive to CsA, perhaps reflecting their derivation from a functionally
distinct B cell population with enhanced drug sensitivity.
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INTRODUCTION
Cyclosporine (CsA) is a fungal metabolite with novel immunosuppressive properties. This agent
acts selectively on lymphoid cells and suppresses immune function primarily by clocking the
production and response to interleukin 2 by T lymphocytes (Borel et al., 1977; Britton & Palacios,
1982; Calne, 1979; Cohen et al., 1984). The inhibition of cellular immune function without
myelotoxicity has contributed to the value of CsA in the treatment of organ graft rejection. CsA
displays other actions that may be useful in immunological studies as well as the clinical setting. In
both human and murine systems, CsA can directly inhibit B cell proliferation and antibody
production independent of T cell influence (Paavanen et al., 1981; Delespesse et al., 1983; Berger,
Meingassner & Knapp, 1983; Muraguchi et al., 1983). The interference with B cell function occurs
at an early stage in activation, although in the mouse, interestingly, it is not uniform among B cell
populations. Thus, CsA preferentially affects murine B cells responding to stimulation with anti-i
as well as certain T cell independent antigens (Kunkl & Klaus, 1980; Dongworth & Klaus, 1982).
The in vitro production ofanti-DNA autoantibody by murine spleen cells has also been shown to be
more sensitive to CsA than other antibody responses (Mayus, Semper & Pisetsky, 1985). These
observations have suggested that CsA can selectively modify certain antibody responses, serving as
pharmacologic marker of functional B cell populations.
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The suppressive action of CsA for B and T lymphocytes has also led to interest in its use as a
selective agent in lymphoproliferative disorders. Indeed, CsA was shown to inhibit the in vitro
proliferation of long-term human T cell tumour lines. This effect was demonstrated at dose levels
which were inactive against other non-T cell hematopoietic cell lines, including human and monkey
B cell lines as well as a murine plasmacytoma (Fou et al., 1981; Berger et al., 1982). In other
investigations, CsA failed to inhibit the growth of Ebstein-Barr virus transformed human B cells
(Graham Bird et al., 1981). These results have suggested a selective anti-proliferative activity
against T cell tumours among transformed lymphoid cells, although the number of B cell lines
examined thus far has been small.
We have therefore questioned whether greater inhibitory activity against B cell tumours could
be demonstrated among other lines, particularly those derived from populations which normally
have enhanced CsA sensitivity. To investigate this possibility, we analysed the response to CsA of a
B cell tumour termed CH12 (Lanier et al., 1982; Arnold et al., 1983; LoCascio et al., 1984). CH12
was derived from a mouse of the B1O.A-2aH-4bp/wts strain. It bears cell surface IgM and can be
stimulated to production of a monoclonal antibody product which binds bromelain-treated mouse
red blood cells (RBC) as well as sheep RBC. The presence of the cell surface marker Lyt- I as well as
the production of an autoantibody product (anti-bromelain-treated mouse RBC) suggests that
CH12 may be derived from the B cell population with greater CsA sensitivity. Moreover, since
CH12 responds to lipopolysaccharide (LPS) as well as T cell signals plus antigen, this tumour
demonstrates certain activation properties in common with early resting B cells and may therefore
be more drug sensitive. In this communication, we present evidence that CsA blocks spontaneous
antibody production and proliferation of CH 12 cells in vitro. These results indicate that sensitivity
to CsA may be retained by malignantly transformed B cells and suggests the use ofCH12 as a model
to investigate the anti-proliferative activity of CsA against B cell tumours.
MATERIALS AND METHODS
Cells and mice. CH 12 cells were maintained in ascites form in strain B10.A mice purchased from
the Jackson Laboratory (Bar Harbor, ME, USA). In some experiments, cells were briefly passed in
culture prior to use. The following cells lines used as controls were provided by Dr J. Brice
Weinberg, Durham VA Hospital: U937 (human monoblastic cell), K562 (human erythroid/chronic
myeloid cell) and HeLa (human epithelial carcinoma).
Cyclosporine and mitogens. The powder form of CsA was the generous gift of Sandoz
Pharmaceuticals (East Hanover, NJ, USA). A stock solution of 2 mg/ml was prepared by first
dissolving the powder in 0-25 ml of 96% ethanol. Following addition of 0 1 ml of Tween 80, the
volume was brought to 3 5 ml with phosphate buffered saline (PBS). LPS from E. coli 0127.B8
(Difco Laboratories, Detroit, MI, USA) was used at a concentration of 2 5 yg/ml while
Concanavalin A (Pharmacia, Uppsala, Sweden) was used to a concentration of 5 yg/ml.
Cell cultures. CH 12 cells, obtained by ascites tap or from passage in culture, were first washed
with Dulbecco's modified Eagle medium (DMEM) media and then suspended in RPMI 1640 media
(Gibco, Grand Island, NY, USA) supplemented with 10% fetal calf serum, 2 x 10-5 M 2-
mercaptoethanol and antibiotics. For these experiments, T cell depleted populations were obtained
by treating cells with two monoclonal anti-T cell reagents HO- 13-4 recognizing Thy-1.2 (Marshak-
Rothstein et al., 1979) and C3PO recognizing Lyt-1.2 (Mark et al., 1982) followed by guinea pig
serum as complement source. Although CH12 displays the Lyt-1.2 antigen, it was possible
nevertheless to use C3PO for T cell killing since CH12 viability was unaffected by this antibody at
the concentrations used. After counting, cells were diluted usually to 5 x 104_5 x 105 cells/ml in
media with or without CsA or LPS. For antibody assays, cells were cultured in 24 well plates
(Linbro, Flow Laboratories, McLean, VA, USA) using a total volume of 0 6 ml. For proliferation
assays cells were cultured using 96 well microtitre plates with a final volume of 0 2 ml. Cells were
incubated for 5-7 days at 37°C in 7% CO2 atmosphere before harvesting. Viable cell counts were
determined by microscopy after staining with Trypan blue.
Antibody assays. Total IgM levels were determined by enzyme-linked immunosorbent assay
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(ELISA) as described elsewhere (Mayus et al., 1985). Briefly, Dynatech microtitre plates were
coated with the F(ab')2 fragment of goat anti-mouse IgG (F(ab')2 specific; Cappel Laboratories,
Cochranville, PA, USA) at 3 pg/ml in PBS. Plates were then washed with PBS containing 0.0500
Tween 20 (PBS-T) and then incubated with various dilutions of culture supernatant for 1 h at room
temperature. Following additional washing, plates were exposed sequentially to a 1:4000 dilution
of rabbit anti-mouse IgM (Litton Bionetics, Charleston, SC, USA) for 1 hr at room temperature
and then peroxidase conjugated goat anti-rabbit IgG (Litton Bionetrics). The final step after
washing with PBS-T was incubation with the peroxidase substrate 3,3',5,5',-tetramethylbenzidine
in pH 4 citrate buffer containing H202. Optical densities were determined at 380 nm using a Titertek
Multiskan platereader. Results are reported in terms of OD380 units.
Proliferation assay. After culture, cells in microtitre plates were pulsed for 6 h with one 1iCi
methyl-3H-Thymidine (2Ci/mm, Amersham, Arlington Heights, IL, USA) per well. The cells were
harvested onto glass paper using a 24 channel microharvester (Bellco Glass, Vineland, NJ, USA)
and radioactivity measured in Aquasol-2 counting fluid (New England Nuclear, Boston, MA,
USA) using a Packard 3375 liquid scintillation spectrometer. The mean and standard deviation of
quadruplicate cultures were obtained.
RESULTS
The activity of CsA on CH12 was tested in vitro measuring proliferation by tritiated thymidine
incorporation as well as antibody production by ELISA. Figure 1 shows results of a representative
experiment demonstrating that CsA caused a profound decrease in thymidine incorporation
achieving 50% inhibition at approximately 100 ng/ml with complete inhibition at 1 0 yg/ml. These
dose levels are comparable to those reported to inhibit T cell lines (Berger et al., 1982). The action of
CsA on CH12 was also reflected in viable cell counts which decreased over the duration of this
experiment. Furthermore, CsA inhibited the spontaneous production of antibody by CH12 over
the same dose range (Fig. 1). Since this tumour was maintained by passage in animals, we
questioned whether some of the CsA inhibition resulted from inhibition of growth factor
production by T cells present among the tumour. The preparations obtained from the animals failed
to show stimulation by concanavalin A. Moreover, the experiments were repeated with tumour cell
preparations depleted of T cells by treatment with monoclonal anti-T cell reagents which were
inactive against CH12 despite its expression of Lyt-l. These preparations showed the same
sensitivity to CsA as untreated populations (data not shown), arguing against an indirect effect of
CsA.
It was important next to establish that the antiproliferative effect ofCsA on CH 12 did not result
from non-specific toxicity to cultured cells. Although previous experiments demonstrated resistance
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Fig. 1. CsA Inhibition ofCH 12 proliferation and antibody production. CH 12 cells were grown in tissue culture
with various concentrations ofCsA. Proliferation was measured by the incorporation of tritiated thymidine (0)
while antibody production was measured by ELISA (A). CH12 cells were present at 5 x IO' cells/ml.
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Fig. 2. CsA inhibition oftumour cell lines. The effect ofCsA on proliferation oftumour cell lines was tested using
CH12, U937, K562 and HeLa cells. (0) Proliferation in the absence of CsA; (a, U, *) proliferation in the
presence of0 1,0 5 and 5 pg/ml ofCsA respectively. Cell concentrations were selected to give equivalent degrees
of tritiated thymidine incorporation and varied for the different cell lines, including CH12 (I05 cells/ml) U937
(5 x 104 cells/ml), K562 (104 cells/ml) and HeLa (104 cells/ml). Inhibition patterns were independent of cell
numbers, however, over a five-fold range.
of many cell lines to CsA (Berger et al., 1982) we retested a series of cell lines under our culture
conditions. As shown in Fig. 2, at doses of CsA which completely blocked proliferation of CHI 2,
three other cell lines were unaffected. Some inhibition of proliferation was noted, however, at very
high doses ofCsA although this inhibition was only partial and required concentrations ofCsA 10-
to 50-fold greater to achieve levels of inhibition comparable to that observed for CH12.
In normal B cells, stimulation by LPS produces resistance to CsA presumably by providing a
signal for activation that bypasses a CsA sensitive step (Klaus & Hawrylowicz, 1984). Since CH12
responds to LPS, we tested the influence of this mitogen on CsA sensitivity. As shown in Fig. 3, cells
stimulated by LPS were more resistant to CsA than unstimulated cells, an effect observed with
antibody production as well as proliferation. This effect was observed, moreover, over a range of
cell numbers tested (5 x 104 to 5 x I05). Thus, as in the case of normal B cells, CHI2 sensitivity may
reflect the nature of the signal producing activation.
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Fig. 3. Effect of LPS on CsA sensitivity ofCH 12. The sensitivity ofCH 12 proliferation to CsA was tested with
and without 2 5 ,ug/ml of LPS. In these experiments, LPS was present from the initiation of culture, with
proliferation determined after 5 days. (o) Activity without LPS; (0) activity with LPS. Each point represents the
average of determinations from two separate experiments. Proliferation values for cultures without LPS were
46,253 + 2350 and 69,190+4083 while those with LPS were 89,175 +4709 and 124,929 +4162.
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DISCUSSION
These studies provide further evidence for a direct action of CsA on B cells and indicate moreover
that sensitivity to this agent may be retained by malignantly transformed cells. These findings
parallel studies on T cell lines whose in vitro proliferation were inhibited by CsA (Fou et al., 1981;
Berger et al., 1982). Together, they suggest that monoclonal tumour cell preparations ofB as well as
T cell origin may be useful for delineating the mechanisms ofCsA action. In addition, they indicate
that CsA may be an effective probe for growth regulation in selected lymphoid malignancies.
At least two mechanisms can explain the inhibition ofCH 12 growth and function by CsA. The
first is that CH 12 is derived from a B cell population with intrinsic sensitivity to this agent. There is a
difference among B cell populations in their response to CsA with those responding to certain T-
independent antigens preferentially inhibited (Kunkl & Klaus, 1980; Dongworth & Klaus, 1982).
There is evidence moreover that autoantibody producing B cells are more sensitive to CsA than
others (Mayus et al., 1985). CH 12 produces an antibody product to bromelain-treated mouse RBC
that is sometimes characterized as an autoantibody. In addition, CH 12 bears the cell surface marker
Lyt-l which is expressed by autoantibody producing B cells (Hayakawa et al., 1984). The simplest
interpretation ofthese findings is that growth inhibition ofCH 12 by CsA reflects its origin from a B
cell population which characteristically enhanced sensitivity to this agent.
An alternative explanation is that CH 12 is in a state of activation or differentiation that is CsA
sensitive although not dependent on its derivation in a particular B cell population. CH12 has
features suggestive of an early resting B cell and retains responsiveness to certain signals for
stimulation. This functional state may be the determinant of CsA sensitivity. It is noteworthy that
treatment of CH12 with LPS reduces sensitivity to CsA. This result suggests that stimulation by
mitogen bypasses an activation step that is the target site ofCsA. In this view, the sensitivity ofCsA
may be dependent on the activation pathway of a cell rather than membership in a particular
population. It will be ofinterest therefore to determine the scope ofB cell tumours that are inhibited
by CsA in both human and murine systems and the cell functional markers that are associated with
this property.
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